New CLL strategy: only add extra drug if needed
NCT ID NCT05650723
First seen Mar 07, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This phase 2 trial tests a personalized approach for chronic lymphocytic leukemia (CLL). Patients first receive two oral drugs (zanubrutinib and venetoclax). Only those with remaining cancer cells after treatment get an additional infusion drug (obinutuzumab). The goal is to see if this strategy can clear the cancer while avoiding unnecessary side effects. About 50 adults with CLL are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib, venetoclax, and obinutuzumab
What this could lead to
If successful, this approach could offer a more personalized treatment for CLL, reducing side effects by giving additional therapy only to those who need it.
What could go wrong
This is a small, early-phase trial (50 participants) with no control group. The strategy may not improve outcomes and could still cause side effects from the drugs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.